

Eric Pujade-Lauraine

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2758528/publications.pdf>

Version: 2024-02-01

15
papers

3,053
citations

1040056

9
h-index

996975

15
g-index

16
all docs

16
docs citations

16
times ranked

3918
citing authors

#	ARTICLE	IF	CITATIONS
1	Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1274-1284.	10.7	1,376
2	Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 2416-2428.	27.0	1,176
3	Clinical Trials in Recurrent Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 771-775.	2.5	186
4	Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase. <i>Gynecologic Oncology</i> , 2016, 140, 457-462.	1.4	159
5	European Network of Gynaecological Oncological Trial Groups' Requirements for Trials Between Academic Groups and Pharmaceutical Companies. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 476-478.	2.5	38
6	Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): A Korean Gynecologic Oncology Group study (KGOG 3041). <i>Gynecologic Oncology</i> , 2019, 152, 61-67.	1.4	26
7	European Network of Gynaecological Oncological Trial Groups'™ Requirements for Trials Between Academic Groups and Industry Partners'™ First Update 2015. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 1328-1330.	2.5	22
8	Development and validation of a prognostic nomogram for overall survival in patients with platinum-resistant ovarian cancer treated with chemotherapy. <i>European Journal of Cancer</i> , 2019, 117, 99-106.	2.8	17
9	Incidence of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients (pts) with a germline (g) <i>BRCA</i> mutation (m) and platinum-sensitive relapsed ovarian cancer (PSR OC) receiving maintenance olaparib in SOLO2: Impact of prior lines of platinum therapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5548-5548.	1.6	13
10	Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy. <i>European Journal of Cancer</i> , 2021, 154, 190-200.	2.8	9
11	Concordance of BRCA mutation detection in tumor versus blood, and frequency of bi-allelic loss of BRCA in tumors from patients in the phase III SOLO2 trial. <i>Gynecologic Oncology</i> , 2021, 163, 563-568.	1.4	9
12	Safety of bevacizumab in clinical practice for recurrent ovarian cancer: A retrospective cohort study. <i>Oncology Letters</i> , 2016, 11, 1859-1865.	1.8	8
13	Evaluation of surgical resection in advanced ovarian, fallopian tube, and primary peritoneal cancer: laparoscopic assessment. A European Network of Gynaecological Oncology Trial (ENGOT) group survey. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 819-824.	2.5	7
14	Olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer: Japan subset from the PAOLA-1/ENGOT-ov25 trial. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e82.	2.2	6
15	Analysis of tumor samples from SOLO2: Concordance of <i>BRCA</i> mutation (<i>BRCA</i> m) detection in tumor vs. blood and frequency of <i>BRCA</i> -specific loss of heterozygosity (LOH) and loss of function somatic mutations.. <i>Journal of Clinical Oncology</i> , 2018, 36, 12017-12017.	1.6	1